Medication therapy management (MTM), is a service model aimed at helping general health problems by preventing morbidity and mortality. Hypertension is a non-communicable disease which is a serious health problem which requires long-term therapy.  This study aims to see the effect of MTM on clinical Outcomes and quality of life of patients in hypertensive patients. This type of research is a quasi experimental one group with a pretest-posttest design. Analysis using paired sample t-test and Wilcoxon test with a significance used P <0,05. Respondents were 70 people, 67,1% were women. The characteristics of the majority age are 55-64 years with a percentage of 51,4%, the majority of education level is high school with 42,8%, non-civil servant jobs with a percentage of 45,7%, the length of diagnosis is dominated by 1-10 years (77,1%) and comorbidities diabetes mellitus occurred the most (10,0%). The results showed that the quality of life increased from before getting MTM 54,4 ± 8,9 and after MTM intervention 60,4 ± 6,6 (P value <0,001). Clinical outcome from systolic 159,2 ± 8,9 mmHg and diastolic 103,8 ± 8,0 mmHg before MTM to 144,1 ± 14,4 mmHg for systolic and 89,7 ± 8,8 mmHg for diastolic with p value <0,001 (p <0,05) for systolic blood pressure and p value: 0,016 (p <0,05) after receiving MTM intervention. Medication Therapy Management (MTM) has a significant influence on improving the quality of life and clinical Outcomes of hypertensive patients. The higher the quality of life of patients, blood pressure becomes more controlled.

Nifedipine is a drug that acts as an antihypertensive and anti-angina. Nifedipine is known as a drug with poor water solubility. This characteristic will affect the intrinsic dissolution rate so that it can affect the absorption process and reduce the amount of drug that reaches systemic circulation. One of the strategies to increase the intrinsic dissolution rate is developing nifedipine to solid dispersions form. This study aims to observe the intrinsic dissolution rate of nifedipine after it has been made into a solid dispersion. Four samples were prepared, including three solid dispersions of nifedipine-PVP K-30 and one sample of pure nifedipine. The results of the intrinsic dissolution tests are then interpreted through the intrinsic dissolution rate constant (G). The solid dispersions with concentration of nifedipine-PVP K-30 90%:10%; 75%:25%; 60%:40% (w/w), and pure nifedipine produced G values of 3.63; 9.33; 12.63; and 2.08 µg/mm2. min1, consecutively. It shows that the formulation of nifedipine-PVP K-30 solid dispersions has higher G values than pure nifedipine. In addition, increasing PVP K-30 concentration up to 40 % (w/w) can increase the intrinsic dissolution rate of the nifedipine-PVP K-30 solid dispersion system.